Alzheimer's Disease: Antibody Solanezumab has no Effect in the preclinical Stage

被引：0
|
作者：
Simon, Annika
机构：
来源：
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE | 2024年 / 92卷 / 07/08期
关键词：
D O I：
10.1055/a-2304-0921
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Humane monoklonale Antikorper zur Bindung verschiedener Amyloid-Formen gelten als gro ss e Hoffnung im Kampf gegen die Alzheimer-Demenz. So konnte der Antikorper Solanezumab in ersten Studien Amyloid-Monomere binden und eine gewisse neuroprotektive Funktion ubernehmen. Sperling et al. haben daher die Wirksamkeit von Solanezumab bei PatientInnen im praklinischen Stadium genauer betrachtet und
引用
收藏
页码：261 / 262
页数：2
相关论文
共 50 条
  • [21] Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease
    Honig, Lawrence S.
    Vellas, Bruno
    Woodward, Michael
    Boada, Merce
    Bullock, Roger
    Borrie, Michael
    Hager, Klaus
    Andreasen, Niels
    Scarpini, Elio
    Liu-Seifert, Hong
    Case, Michael
    Dean, Robert A.
    Hake, Ann
    Sundell, Karen
    Hoffmann, Vicki Poole
    Carlson, Christopher
    Khanna, Rashna
    Mintun, Mark
    DeMattos, Ronald
    Selzler, Katherine J.
    Siemers, Eric
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (04): : 321 - 330
  • [22] Safety and biomarker effects of Solanezumab in patients with Alzheimer's disease
    Farlow, Martin
    Amold, Steven E.
    van Dyck, Christopher H.
    Aisen, Paul S.
    Snider, B. Joy
    Porsteinsson, Anton P.
    Friedrich, Stuart
    Dean, Robert A.
    Gonzales, Celedon
    Sethuraman, Gopalan
    DeMattos, Ronald B.
    Mohs, Richard
    Paul, Steven M.
    Siemers, Eric R.
    ALZHEIMERS & DEMENTIA, 2012, 8 (04) : 261 - 271
  • [23] Trial of solanezumab for mild dementia due to Alzheimer's disease
    Pickrell, William O.
    Robertson, Neil P.
    JOURNAL OF NEUROLOGY, 2018, 265 (09) : 2162 - 2162
  • [24] Disappointing phase 3 results for solanezumab for Alzheimer's disease
    不详
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2023, 27 (02) : 42 - 42
  • [25] Solanezumab for the treatment of mild-to-moderate Alzheimer's disease
    Imbimbo, Bruno P.
    Ottonello, Simone
    Frisardi, Vincenza
    Solfrizzi, Vincenzo
    Greco, Antonio
    Seripa, Davide
    Pilotto, Alberto
    Panza, Francesco
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2012, 8 (02) : 135 - 149
  • [26] A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
    Stephen Salloway
    Martin Farlow
    Eric McDade
    David B. Clifford
    Guoqiao Wang
    Jorge J. Llibre-Guerra
    Janice M. Hitchcock
    Susan L. Mills
    Anna M. Santacruz
    Andrew J. Aschenbrenner
    Jason Hassenstab
    Tammie L. S. Benzinger
    Brian A. Gordon
    Anne M. Fagan
    Kelley A. Coalier
    Carlos Cruchaga
    Alison A. Goate
    Richard J. Perrin
    Chengjie Xiong
    Yan Li
    John C. Morris
    B. Joy Snider
    Catherine Mummery
    G. Mustafa Surti
    Didier Hannequin
    David Wallon
    Sarah B. Berman
    James J. Lah
    Ivonne Z. Jimenez-Velazquez
    Erik D. Roberson
    Christopher H. van Dyck
    Lawrence S. Honig
    Raquel Sánchez-Valle
    William S. Brooks
    Serge Gauthier
    Douglas R. Galasko
    Colin L. Masters
    Jared R. Brosch
    Ging-Yuek Robin Hsiung
    Suman Jayadev
    Maité Formaglio
    Mario Masellis
    Roger Clarnette
    Jérémie Pariente
    Bruno Dubois
    Florence Pasquier
    Clifford R. Jack
    Robert Koeppe
    Peter J. Snyder
    Paul S. Aisen
    Nature Medicine, 2021, 27 : 1187 - 1196
  • [27] Biotinylated antibody as a tool to diagnose preclinical Alzheimer's disease.
    Oh, E. S.
    Tucker, S.
    Borchelt, D.
    Troncoso, J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (04) : S163 - S163
  • [28] Phase 3 Trials of Solanezumab and Bapineuzumab for Alzheimer's Disease REPLY
    Doody, Rachelle S.
    Farlow, Martin
    Aisen, Paul S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (15): : 1460 - 1460
  • [29] Grasping at straws: the failure of solanezumab to modify mild Alzheimer's disease
    Doggrell, Sheila A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (12) : 1189 - 1192
  • [30] Preclinical Alzheimer's disease
    Gil-Gregorio, P.
    Yubero-Pancorbo, R.
    REVIEWS IN CLINICAL GERONTOLOGY, 2014, 24 (02) : 117 - 121
12345